Adaptive Treatment for Adolescent Cannabis Use Disorders
Cannabis Use Disorder
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
|Official Title:||Adaptive Treatment for Adolescent Cannabis Use Disorders|
- 1.) To evaluate the efficacy of AT for youth who have been defined as poor responders to an evidence-based practice intervention such as the initial MET/CBT-7. [ Time Frame: one year ]Each participant will serve as his/her own control. The outcomes will include the T-ASI, T-ASI-P, and drug urinalyses.
- To assess outcomes as a function of mediator variables such as self-efficacy, coping skills, readiness to change, and environmental support (i.e., family and peer), within each of the AT interventions. [ Time Frame: one year ]The secondary outcome measures will include the SCQ, CRI, PRQ, and SSQ.
|Study Start Date:||September 2011|
|Study Completion Date:||July 2016|
|Primary Completion Date:||July 2016 (Final data collection date for primary outcome measure)|
Ten weekly 60-minute sessions of Adolescent Community Reinforcement Approach (ACRA) will be provided as an Adaptive treatment condition.
Ten weekly,60-minute therapy sessions including six individual, two parent/guardian and two joint (individual and parent/guardian).
Other Name: Adolescent Community Reinforcement Approach
Experimental: Cognitive Behavioral Therapy (CBT)
Ten weekly, 60-minute sessions of augmented individualized Cognitive Behavioral Therapy (CBT)will be provided as an Adaptive Treatment condition
10 weekly, 60-minute sessions of augmented individualized CBT
Other Name: Cogntive Behavioral Therapy
The study will address the current contrasts in youth response to treatment, the problem of poor response to treatment and the prevention of relapse. Results from the study may support Adaptive Treatment as an efficacious approach for youth with Cannabis Use Disorder who are poor responders to treatment.
Poor responders fall into two categories, those who failed to achieve a negative drug urinalysis during the last session of the initial MET/CBT-7 treatment they attended, and those who either dropped out or were administratively discharged at any time during the initial MET/CBT-7 treatment.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01656707
|United States, Connecticut|
|University of Connecticut Health Center|
|Farmington, Connecticut, United States, 06030-2103|
|Principal Investigator:||Yifrah Kaminer, MD, MBA||UConn Health|